Patents whose numbers are in italics have been extended under 35 USC 156. Unless otherwise noted, all expiration dates include applicable Sec. 156 and pediatric (PED) extensions.
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 6902734 [Extended 425 days (1.2 years)] Anti-IL-12 antibodies and compositions thereof Claim Types: Compound; Composition Pat. Sub. Date(s): None | Sep 25, 2023 | |
| Pat. No. 8852889 Cell culture process Claim Types: Process Pat. Sub. Date(s): None | Jul 6, 2032 | |
| Pat. No. 9217168 Methods of cell culture Claim Types: Process Pat. Sub. Date(s): None | Mar 14, 2033 | |
| Pat. No. 9475858 Cell culture process Claim Types: Process Pat. Sub. Date(s): None | Jul 6, 2032 | |
| Pat. No. 9663810 Methods of cell culture Claim Types: Process Pat. Sub. Date(s): None | Mar 14, 2033 | |
| Pat. No. 10961307 Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody Claim Types: Method of use Pat. Sub. Date(s): None | Sep 24, 2039 |
ustekinumab (Injection) (Intravenous) Stelara
NDA Applicant: Janssen Biotech, Inc. BLA No.: 761044 Prod. No.: 001 Rx (130MG/26ML (5MG/ML))
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 6902734 [Extended 425 days (1.2 years)] Anti-IL-12 antibodies and compositions thereof Claim Types: Compound; Composition Pat. Sub. Date(s): None | Sep 25, 2023 | |
| Pat. No. 8852889 Cell culture process Claim Types: Process Pat. Sub. Date(s): None | Jul 6, 2032 | |
| Pat. No. 9217168 Methods of cell culture Claim Types: Process Pat. Sub. Date(s): None | Mar 14, 2033 | |
| Pat. No. 9475858 Cell culture process Claim Types: Process Pat. Sub. Date(s): None | Jul 6, 2032 | |
| Pat. No. 9663810 Methods of cell culture Claim Types: Process Pat. Sub. Date(s): None | Mar 14, 2033 | |
| Pat. No. 10961307 Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody Claim Types: Method of use Pat. Sub. Date(s): None | Sep 24, 2039 |